ARCHIMED (private equity) / Esperion Therapeutics Inc.

Hyperlipidemia / Atherosclerotic Cardiovascular Disease (ASCVD)

86M US cases/yr · $25.0B US Market

Disease Overview

Hyperlipidemia, characterized by elevated low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipid fractions, is the central modifiable driver of atherosclerotic cardiovascular disease (ASCVD), the leading cause of death in the United States. CDC data indicate roughly 86 million US adults aged 20 and older have total cholesterol above 200 mg/dL, and approximately 28 million have LDL-C above 130 mg/dL. Statins remain the cornerstone of LDL-C reduction and have demonstrated 25-50% reductions in cardiovascular events across primary and secondary prevention populations. Despite their efficacy, an estimated 10-15% of patients are statin-intolerant due to musculoskeletal or hepatic side effects, and a substantial fraction of high-risk patients fail to reach guideline LDL-C targets even on maximum tolerated statin therapy. The 2026 ACC/AHA dyslipidemia guideline update granted multiple Class 1 recommendations to bempedoic acid (Nexletol/Nexlizet), Esperion's oral ATP-citrate lyase inhibitor that reduces LDL-C ~17-25% and demonstrated cardiovascular event reduction in the CLEAR Outcomes trial. The non-statin LDL-lowering market also includes injectable PCSK9 monoclonal antibodies (Repatha, Praluent), siRNA inclisiran (Leqvio), and ezetimibe. Merck's oral PCSK9 inhibitor MK-0616 (enlicitide) cleared late-stage trials in 2025 and threatens to compress the oral non-statin segment. The US lipid-lowering market exceeds $25 billion and is expanding as guidelines push lower LDL-C targets and broader high-risk population coverage.

Competitive Landscape

Esperion's bempedoic acid franchise (Nexletol monotherapy and Nexlizet ezetimibe combination) competes in a crowded non-statin LDL-lowering market against injectable PCSK9 monoclonal antibodies Repatha (Amgen) and Praluent (Sanofi/Regeneron), Novartis's siRNA Leqvio (inclisiran), and generic ezetimibe. Bempedoic acid's differentiation rests on (1) oral once-daily dosing versus injectable PCSK9s, (2) cardiovascular outcomes evidence from CLEAR Outcomes, and (3) the 2026 ACC/AHA Class 1 guideline endorsements that materially strengthened payer access leverage. The near-term competitive threat is Merck's oral PCSK9 inhibitor enlicitide (MK-0616), which posted positive Phase 3 results in 2025 and could capture share in the same statin-intolerant and add-on niches if approved. ARCHIMED's $3.16 cash plus up to $100M CVR (with $40M tied to 2027 bempedoic acid sales above $350M and $60M to bumetanide-Enbumyst sales above $160M) reflects measured upside expectations: the upfront alone represents only modest incremental value over recent trading and assumes the public-market vehicle had limited remaining capital-efficient growth path. Take-private structure removes quarterly earnings pressure and enables longer commercial-cycle investment.